ArticlePrimary care companion to the Journal of clinical psychiatry2009
Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.
Article in Primary care companion to the Journal of clinical psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 151 citations in OpenAlex.
- Pooled it
- Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence.CNS neuroscience & therapeutics · 2021Pooled it
- Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis.Systematic reviews · 2020Pooled it
- Assessing Usage and Usability of a Narrative-Based Psychoeducational Digital Intervention to Improve Medication Adherence Among Individuals With Schizophrenia in a Stable Phase: Mixed Methods Study.Journal of medical Internet research · 2026Trial
- MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.Addiction science & clinical practice · 2018Trial
- Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia.Clinical pharmacokinetics · 2017Trial
- Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.Journal of psychopharmacology (Oxford, England) · 2015Trial
- Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.BMC psychiatry · 2012Trial
- Impact of Healthcare Professional Role and Care Setting on Attitudes Toward Long-Acting Injectable Antipsychotics for Schizophrenia: A Subgroup Analysis of the Multinational ADVANCE Study.Schizophrenia bulletin open · 2026Article
- Effectiveness of antipsychotic medication in patients with schizophrenia in a real world retrospective observational study in Ethiopia.Scientific reports · 2025Observational
- Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study.Journal of managed care & specialty pharmacy · 2024Observational
- Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents.Schizophrenia research · 2023Review
- Examining clinician choice to follow-up (or not) on automated notifications of medication non-adherence by clinical decision support systems.BMC medical informatics and decision making · 2023Article
- Factors associated with medication interruption among outpatients with severe mental illness exposed to COVID-19.Frontiers in public health · 2023Article
- Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia".PharmacoEconomics · 2022Article
- Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2022Article
- Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2022Article
- Mental Health Care Provider's Perspectives Toward Adopting a Novel Technology to Improve Medication Adherence.Psychiatric research and clinical practice · 2022Article
- Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis.Frontiers in psychiatry · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough many clinicians acknowledge the occurrence of adherence problems with medication regimens among patients with schizophrenia, the problem shows no sign of improving. This may be because, in thinking about the issue, clinicians have tended to focus on patients who openly refuse or repeatedly discontinue treatment. While this description applies to only a minority of patients, in our experience, full adherence is rare; most patients are only partially adherent at best. This article examines the issue of adherence behavior in schizophrenia, focusing on the impact of partial adherence on treatment outcomes, particularly early in the course of illness. We also review potential strategies for managing the problem. DATA SOURCES: Original research and review articles published in English from 1980 to 2008 were identified using the PubMed database, with the search terms schizophrenia or psychosis combined with compliance, noncompliance, partial compliance, adherence, nonadherence, or partial adherence. STUDY SELECTION: Articles were selected by the authors on the basis of the hypotheses and/or data described. DATA SYNTHESIS: Failure to adhere to medication as prescribed can have a major impact on the course of illness and treatment outcomes in patients with schizophrenia. Even relatively short gaps in medication coverage increase the risk of relapse. Problems with adherence are common early in the course of illness, when the consequences of relapse can be particularly devastating.
conclusionClinicians in primary care and psychiatric settings need to be vigilant for signs of adherence problems among their patients and to act when necessary to prevent or alleviate the consequences of inadequate medication cover. Relapse prevention strategies, particularly for patients with early psychosis, should include ensuring that medication lapses are minimized or eliminated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.